Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (Beijing Boren Hospital)
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (Beijing Boren Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy being investigated for the treatment of various B-cell mediated autoimmune diseases. Developed by Beijing Boren Hospital, the therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically targets the CD19 antigen, which is ubiquitously expressed on B-lineage cells. By targeting and eliminating these B cells, the therapy aims to deplete the source of pathogenic autoantibodies and reset the immune system. Clinical investigations at Beijing Boren Hospital have focused on patients with refractory conditions such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy, and other B-cell related autoimmune disorders.
- Other names
- CAR-T cells-Beijing Boren Hospital-autoimmune diseasesanti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCAR-T cells targeting B cell related autoimmune diseases
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (Beijing Boren Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (Beijing Boren Hospital).